Category: carcinoid and neuroendocrine tumor treatments

CCF Facebook LIVE Announcement Xavier Keutgen (1)

Cytoreductive Surgery: Why, When, & How often?

April 3, 2019
a Q&A with Neuroendocrine Cancer Surgical Oncologist, Xavier Keutgen, MD

 

 

The Carcinoid Cancer Foundation recently presented a Live Q&A session with Dr. Xavier Keutgen, discussing surgery for people living with neuroendocrine…

READ MORE
Lowell B. Anthony, MD_2

Markey Cancer Center to Host OncLive Summit on Neuroendocrine Tumors

March 19, 2019

The UK Markey Cancer Center in Lexington, Kentucky, will host OncLive’s State of the Science Summit on Neureoendocrine Tumors (NETs) on Saturday, April 20, 2019. The Summit is “designed to educate healthcare professionals on the clinical benefits …

READ MORE
Ignyta Chief Medical Officer, Pratik Mutani, MD

STARTRK-2: A Basket Trial for Neuroendocrine Tumor Patients with Specific Gene Rearrangements

April 7, 2017

Precision medicine, molecular testing, basket studies, STARTRK-2 – it may sound like technology of the future but it is here today and it might be the answer to slowing or stopping tumor growth for neuroendocrine tumor (NET) patients who have specific…

READ MORE
Edda Gomez-Panzani, MD

In Memoriam: Edda Gomez-Panzani, MD

July 9, 2015

It is with deep sorrow that we learned of the passing of Edda Gomez-Panzani, MD on June 30, 2015. The NorCal CarciNET Community shared a tribute to Edda who “was instrumental in gaining FDA approval for Somatuline (lanreotide) for NETs patients …

READ MORE
Charlotte NC collage_2

2014 National NET Cancer Patient Conference — Registration Now Open

January 30, 2014

Carcinoid and NET (neuroendocrine tumor) cancer patients, caregivers and family members, as well as physicians and other health professionals, have a unique opportunity to learn more about NET cancer, including the latest information about diagnosis…

READ MORE
Alexander Masters

A Possible Cure for Neuroendocrine Cancer: Exciting Update!

June 19, 2013

Back in September 2012 we shared the following:  “For $1.6 million (1 million pounds) an oncolytic virus that has the potential to cure neuroendocrine cancer can be named for the donor.  At Uppsala University in Sweden researchers are ready to start a …

READ MORE
Ebrahim Delpassand, MD

First U.S. Center to Enroll Patients in International, Multicenter Clinical Trial of Lu-177 Octreotate

November 20, 2012

Excel Diagnostics and Nuclear Oncology Center in Houston, Texas, is the first center in the United States to start recruiting patients in a multicenter randomized clinical trial of Lu-177 Octreotate in patients with progressive midgut carcinoid.…

READ MORE
Magnus Essand

A Possible Cure for Neuroendocrine Cancer — It Can Be Named for You or a Loved One

September 1, 2012

For $1.6 million (1 million pounds) an oncolytic virus that has the potential to cure neuroendocrine cancer can be named for the donor.  At Uppsala University in Sweden researchers are ready to start a clinical trial for up to 20 NET (neuroendocrine tumor)…

READ MORE
Tannis Brown

Neuroendocrine Cancer Survivor Featured on Discovery Fit & Health TV Show

July 8, 2012

THIS JUST IN:  Tannis Brown, a pheochromocytoma patient and Vice President of the Pheo Para Troopers, will be featured on the Discovery Fit & Health Network on Monday, July 9 in a program titled Diagnosis: Dead or Alive.* The 60 minute show will focus…

READ MORE

Carcinoid Cancer Foundation’s May 2011 Symposium Now Online

June 23, 2011

The Carcinoid Cancer Foundation is pleased to share with you videos from its carcinoid/NET symposium, “Neuroendocrine Tumor Management:  The Era of Personalized Medicine,” held on May 1, 2011 at Mt. Sinai Medical Center in New York City.

Following …

READ MORE